VeloClub is CyclingTips’ membership program which brings us closer to our members, and connects likeminded cycling enthusiasts.
by Matt de Neef
April 30, 2018
In today’s edition of the CT Daily News Digest: Primoz Roglic wins the Tour de Romandie; Charlotte Becker takes overall win at Tour of Chongming Island; Richard Carapaz takes out the Vuelta Asturias; Surprise win for 18-year-old Letizia Paternoster at Festival Elsy Jacobs; Lieuwe Westra opens up on TUE use for performance enhancement; Chapter2 launches new aero road frameset; Becoming a sports director; Tour of Chongming Island stage 3 with Wiggle High5; Updating the Daily News Digest.
Dutch former pro Lieuwe Westra has opened up about his use of cortisone during his career, revealing in a new book that he relied on TUEs to pass anti-doping tests.
An article over the weekend in the Leeuwarder Courant, the Netherlands’ oldest daily newspaper, reports that Westra writes in his book that he used knee pain as an excuse to obtain TUEs for cortisone. He then used the steroid during important parts of his season.
“The medical certificate I received often with a feigned injury, for example an inflammation in the knee,” Westra writes. “It took years to recover an injury to the knee.
“I shot it in my own body to cycle faster, to grab prizes, to receive compliments. In my first professional year it became clear to me that with only hard training no victories were achieved. If you wanted to join the big boys, you had to look up the limits of the permissible.”
In a statement to the media over the weekend, Team Astana — which Westra rode with from 2014 until he retired in 2016 — said it was “shocked” about Westra’s admission: “We’re shocked to read about Lieuwe Westra and his use of drugs in the period he had a contract with Astana Pro Team, as the team never provided him with any of the medicines that are mentioned in the media today. We want to make clear that at Astana Pro Team forbidden drugs are never and will never be provided to any rider.”
Follow the link to read more at the Leeuwarder Courant.